Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2013

Open Access 01-12-2013 | Research article

Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?

Authors: Lisa Balbach, Henri Wallaschofski, Henry Völzke, Matthias Nauck, Marcus Dörr, Robin Haring

Published in: BMC Endocrine Disorders | Issue 1/2013

Login to get access

Abstract

Background

To investigate potential associations of serum prolactin concentration (PRL) with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM), previously observed in small and selected study samples, in a large population-based cohort.

Methods

Data from 3,993 individuals (2,027 women) aged 20-79 years from the population-based Study of Health of Pomerania (SHIP) were used to analyse cross-sectional and longitudinal associations of PRL with MetS and T2DM risk in age- and multivariable-adjusted Poisson regression models. PRL were log-transformed and modelled as continuous (per standard deviation (SD) increase) and categorical predictor (sex-specific quartiles) variable, separately for men and woman.

Results

Cross-sectional analyses showed an inverse association between low PRL concentrations and prevalent T2DM risk in men and women after multivariable-adjustment (men: Q1 vs. Q4: relative risk (RR), 1.55; 95% confidence interval (CI), 1.13 – 2.14; women: Q1 vs. Q4: RR, 1.70; 95% CI, 1.10 – 2.62). Likewise, higher PRL concentrations were associated with significantly lower T2DM risk (RR per SD increase in log-PRL: 0.83; 95% CI, 0.72 – 0.95 in men, and 0.84; 95% CI, 0.71 – 0.98 in women, respectively). An inverse association between PRL and MetS risk was not retained after multivariable adjustment. Longitudinal analyses yielded no association of PRL with incident MetS or T2DM.

Conclusion

The present study is the first large population-based study reporting a cross-sectional inverse association between PRL and prevalent T2DM in both genders. But the absent longitudinal associations do not support a causal role of PRL as a risk factor of incident MetS or T2DM.
Appendix
Available only for authorised users
Literature
1.
Cejkova P, Fojtikova M, Cerna M: Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev. 2009, 9 (1): 23-27. 10.1016/j.autrev.2009.02.031.CrossRefPubMed
2.
Brandebourg T, Hugo E, Ben-Jonathan N: Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007, 9 (4): 464-476. 10.1111/j.1463-1326.2006.00671.x.CrossRefPubMed
3.
Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR: Focus on prolactin as a metabolic hormone. Trends in endocrinology and metabolism. TEM. 2006, 17 (3): 110-116.PubMed
4.
Prasad H, Ryan DA, Celzo MF, Stapleton D: Metabolic syndrome: definition and therapeutic implications. Postgrad Med. 2012, 124 (1): 21-30. 10.3810/pgm.2012.01.2514.CrossRefPubMed
5.
Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R: Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2008, 93 (10): 3671-3689. 10.1210/jc.2008-0222.CrossRef
6.
Brelje TC, Stout LE, Bhagroo NV, Sorenson RL: Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology. 2004, 145 (9): 4162-4175. 10.1210/en.2004-0201.CrossRefPubMed
7.
Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, Kendall W, Oden J, Bridges S, Binart N: Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology. 2002, 143 (4): 1378-1385. 10.1210/en.143.4.1378.CrossRefPubMed
8.
Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G: The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006, 64 (4): 366-370.
9.
Mingrone G, Manco M, Iaconelli A, Gniuli D, Bracaglia R, Leccesi L, Calvani M, Nolfe G, Basu S, Berria R: Prolactin and insulin ultradian secretion and adipose tissue lipoprotein lipase expression in severely obese women after bariatric surgery. Obesity (Silver Spring). 2008, 16 (8): 1831-1837. 10.1038/oby.2008.297.CrossRef
10.
Ernst B, Thurnheer M, Schultes B: Basal serum prolactin levels in obesity–unrelated to parameters of the metabolic syndrome and unchanged after massive weight loss. Obes Surg. 2009, 19 (8): 1159-1162. 10.1007/s11695-009-9856-0.CrossRefPubMed
11.
Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M: Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl. 2011, 34 (3): 217-224. 10.1111/j.1365-2605.2010.01076.x.CrossRefPubMed
12.
Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G: Cohort profile: the study of health in pomerania. Int J Epidemiol. 2011, 40 (2): 294-307. 10.1093/ije/dyp394.CrossRefPubMed
13.
Haring R, Alte D, Volzke H, Sauer S, Wallaschofski H, John U, Schmidt CO: Extended recruitment efforts minimize attrition but not necessarily bias. J Clin Epidemiol. 2009, 62 (3): 252-260. 10.1016/j.jclinepi.2008.06.010.CrossRefPubMed
14.
Torkler S, Wallaschofski H, Baumeister SE, Volzke H, Dorr M, Felix S, Rettig R, Nauck M, Haring R: Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male. 2011, 14 (3): 176-182. 10.3109/13685538.2010.529194.CrossRefPubMed
15.
Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, Owen L, Adaway J, Keevil BG, Brabant G: Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metabol. 2012, 97 (2): 408-415. 10.1210/jc.2011-2134.CrossRef
16.
Nauck M, Winkler K, Marz W, Wieland H: Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem. 1995, 41 (12 Pt 1): 1761-1767.PubMed
17.
Haring R, Baumeister SE, Völzke H, Dorr M, Felix SB, Kroemer HK, Nauck M, Wallaschofski H: Prospective Association of Low Total Testosterone Concentrations with an Adverse Lipid Profile and Increased Incident Dyslipidemia. Eur J Cardiovasc Prev Rehabil. 2011, 18 (1): 86-96.PubMed
18.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120 (16): 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed
19.
Hannemann A, Meisinger C, Bidlingmaier M, Doring A, Thorand B, Heier M, Belcredi P, Ladwig KH, Wallaschofski H, Friedrich N: Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol. 2011, 164 (5): 751-758. 10.1530/EJE-10-1074.CrossRefPubMed
20.
Schipf S, Alte D, Voelzke H, Friedrich N, Haring R, Lohmann T, Nauck M, Felix SB, Hoffmann W, John U: Prävalenz des Metabolischen Syndroms in Deutschland: Ergebnisse der Study of Health in Pomerania (SHIP). Diabetologie Stoffwechsel. 2010, 5: 161-168. 10.1055/s-0030-1247406.CrossRef
21.
Haring R, Volzke H, Felix SB, Schipf S, Dorr M, Rosskopf D, Nauck M, Schofl C, Wallaschofski H: Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes. 2009, 58 (9): 2027-2031. 10.2337/db09-0031.CrossRefPubMedPubMedCentral
22.
Haring R, Wallaschofski H, Nauck M, Felix SB, Schmidt CO, Dorr M, Sauer S, Wilmking G, Volzke H: Total and cardiovascular disease mortality predicted by metabolic syndrome is inferior relative to its components. Exp Clin Endocrinol Diabetes. 2010, 118 (10): 685-691. 10.1055/s-0030-1261876.CrossRefPubMed
23.
Lidfeldt J, Nyberg P, Nerbrand C, Samsioe G, Schersten B, Agardh CD: Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study. Diabetes Obes Metab. 2003, 5 (2): 106-112. 10.1046/j.1463-1326.2003.00250.x.CrossRefPubMed
24.
25.
Afifi AA, Kotlerman JB, Ettner SL, Cowan M: Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health. 2007, 28: 95-111. 10.1146/annurev.publhealth.28.082206.094100.CrossRefPubMed
26.
Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G: Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009, 6 (5): 1457-1466. 10.1111/j.1743-6109.2008.01206.x.CrossRefPubMed
27.
Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB: The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metabol. 2006, 91 (2): 718-721.CrossRef
28.
Meaney AM, O'Keane V: Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci. 2002, 71 (9): 979-992. 10.1016/S0024-3205(02)01775-7.CrossRefPubMed
29.
Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M: Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry. 1994, 35 (3): 151-163. 10.1016/0006-3223(94)91147-9.CrossRefPubMed
30.
Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003, 160 (2): 284-289. 10.1176/appi.ajp.160.2.284.CrossRefPubMed
31.
Oberweis B, Gragnoli C: Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes. J Cell Physiol. 2012, 227 (8): 3001-3006. 10.1002/jcp.24023.CrossRefPubMed
32.
Muldoon MF, Mackey RH, Williams KV, Korytkowski MT, Flory JD, Manuck SB: Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J Clin Endocrinol Metabol. 2004, 89 (1): 266-271. 10.1210/jc.2003-031295.CrossRef
33.
Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL: Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011, 14 (3): 199-207. 10.1007/s11102-010-0277-9.CrossRefPubMed
34.
dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR: BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011, 19 (4): 800-805. 10.1038/oby.2010.150.CrossRef
35.
Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL: Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol. 2007, 193 (3): 367-381. 10.1677/JOE-07-0043.CrossRefPubMed
36.
Yamamoto T, Ricordi C, Mita A, Miki A, Sakuma Y, Molano RD, Fornoni A, Pileggi A, Inverardi L, Ichii H: beta-Cell specific cytoprotection by prolactin on human islets. Transplant Proc. 2008, 40 (2): 382-383. 10.1016/j.transproceed.2008.01.009.CrossRefPubMedPubMedCentral
37.
Yamamoto T, Mita A, Ricordi C, Messinger S, Miki A, Sakuma Y, Timoneri F, Barker S, Fornoni A, Molano RD: Prolactin supplementation to culture medium improves beta-cell survival. Transplantation. 2010, 89 (11): 1328-1335. 10.1097/TP.0b013e3181d98af1.CrossRefPubMedPubMedCentral
38.
Terra LF, Garay-Malpartida MH, Wailemann RA, Sogayar MC, Labriola L: Recombinant human prolactin promotes human beta cell survival via inhibition of extrinsic and intrinsic apoptosis pathways. Diabetologia. 2011, 54 (6): 1388-1397. 10.1007/s00125-011-2102-z.CrossRefPubMed
39.
Friedrich N, Schneider HJ, Spielhagen C, Markus MR, Haring R, Grabe HJ, Buchfelder M, Wallaschofski H, Nauck M: The association of serum prolactin concentration with inflammatory biomarkers - cross-sectional findings from the population-based Study of Health in Pomerania. Clin Endocrinol (Oxf). 2011, 75 (4): 561-566. 10.1111/j.1365-2265.2011.04075.x.CrossRef
40.
Haring R, Friedrich N, Volzke H, Vasan RS, Felix SB, Dorr M, Meyer Zu Schwabedissen HE, Nauck M, Wallaschofski H: Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J. 2012
41.
Haring R, Volzke H, Vasan RS, Felix SB, Nauck M, Dorr M, Wallaschofski H: Sex-specific associations of serum prolactin concentrations with cardiac remodeling: longitudinal results from the Study of Health Pomerania (SHIP). Atherosclerosis. 2012, 221 (2): 570-576. 10.1016/j.atherosclerosis.2012.01.017.CrossRefPubMed
42.
Katznelson L, Riskind PN, Saxe VC, Klibanski A: Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrinol Metabol. 1998, 83 (3): 761-764. 10.1210/jc.83.3.761.
43.
Maratou E, Hadjidakis DJ, Peppa M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T: Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur J Endocrinol. 2010, 163 (4): 625-630. 10.1530/EJE-10-0246.CrossRefPubMed
44.
Mitrou P, Raptis SA, Dimitriadis G: Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr Rev. 2010, 31 (5): 663-679. 10.1210/er.2009-0046.CrossRefPubMed
45.
Resmini E, Minuto F, Colao A, Ferone D: Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol. 2009, 46 (2): 85-95. 10.1007/s00592-009-0112-9.CrossRefPubMed
46.
Rothman KJ, Greenland S: Causation and causal inference in epidemiology. Am J Public Health. 2005, 95 (Suppl 1): S144-150.CrossRefPubMed
Metadata
Title
Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?
Authors
Lisa Balbach
Henri Wallaschofski
Henry Völzke
Matthias Nauck
Marcus Dörr
Robin Haring
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2013
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-13-12

Other articles of this Issue 1/2013

BMC Endocrine Disorders 1/2013 Go to the issue

Case report

Pituitary and adrenal involvement in diffuse large B-cell lymphoma, with recovery of their function after chemotherapy

Research article

Allograft inflammatory factor 1 (AIF-1) is a new human adipokine involved in adipose inflammation in obese women

Research article

Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in Pomerania

Research article

Younger adult type 2 diabetic patients have poorer glycaemic control: a cross-sectional study in a primary care setting in Singapore

Research article

Insulin resistance and adipokines serum levels in a caucasian cohort of hiv-positive patients undergoing antiretroviral therapy: a cross sectional study

Research article

Relationship of ethnicity and CD4 Count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits